This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Prothena (PRTA) Hit an All-Time High Today

Update (4:10 p.m.): Updated with Wednesday market close information.

NEW YORK (TheStreet) -- Prothena (PRTA - Get Report) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1.

In the wake of this news, RBC Capital Markets increased its target price on Prothena to $52 from $38 and maintained its "outperform" rating. The firm contends that the ISA abstract title indicates that the company's NEOD001 drug produced early cardiac responses in amyloidosis patients. The firm believes this outcome surpasses analysts' estimates and indicates the drug could be worth more than $500 million.

The stock closed at $47.39, up 27.53% or $10.23 from its previous close of $37.16. It amassed a volume of 1,858,633, well above its average of 243,923.

Must Read: Why Lions Gate Entertainment (LGF) Is Falling Today

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PRTA Chart

PRTA data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PRTA $42.98 -8.60%
AAPL $111.04 0.23%
FB $92.63 -1.50%
GOOG $637.93 -0.55%
TSLA $236.05 -4.10%


Chart of I:DJI
DOW 16,776.16 -0.27 -0.00%
S&P 500 1,976.97 -10.08 -0.51%
NASDAQ 4,729.1580 -52.1060 -1.09%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs